Amelparib

Amelparib Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD  
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Company Name: Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd  
Tel: 15317229551
Email: 15151849396@163.com
Company Name: Changzhou Borl Biotechnology Co.,LTD  
Tel: 13656121842
Email: luyan0021@163.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com

Amelparib manufacturers

  • Amelparib
  • Amelparib pictures
  • $3400.00
  • 2026-04-21
  • CAS:1227156-72-0
  • Purity:
  • Supply Ability: 10g
Amelparib Basic information
Product Name:Amelparib
Synonyms:Amelparib;Benzo[h]-1,6-naphthyridin-5(1H)-one, 10-ethoxy-2,3,4,6-tetrahydro-8-(4-morpholinylmethyl)-
CAS:1227156-72-0
MF:C19H25N3O3
MW:343.42
EINECS:
Product Categories:
Mol File:1227156-72-0.mol
Amelparib Structure
Amelparib Chemical Properties
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
Amelparib Usage And Synthesis
UsesAmelparib (JPI-289 free base) is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib inhibits PARP-1 activity (IC50=18.5 nM) and cellular PAR formation (IC50=10.7 nM) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke[1].
in vivo

Amelparib (5, 7.5 and 10 mg/kg, i.v.; single dose) reduces infarct volume in rats with transient and permanent MCAO models by 30% and 53%, respectively, at a dose of 7.5 or 10 mg/kg[2].
Amelparib (10 mg/kg, i.v.; single dose 2 or 8 h after MCAO) reduces mean infarct size and alleviates brain swelling in male SD rats[2].
Amelparib (10 mg/kg, i.v.; single dose 2 h after MCAO) reduces apoptosis of penumbra cells in male SD rats[2].

Animal Model:Male Sprague–Dawley rats[2]
Dosage:10 mg/kg
Administration:Intravenous injection (i.v.), 2 h after MCAO
Result:Reduced the infarct area by 53% and the number of apoptotic cells by 56% after 24 h of administration.
References[1] Kim Y, et al. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. Clin Exp Pharmacol Physiol. 2017;44(6):671-679. DOI:10.1111/1440-1681.12757
[2] Youngchul Kim, et al. Early treatment with poly (ADP-ribose) polymerase-1 inhibitor (JPI-289) reduces infarct volume and improves long-term behavior in an animal model of ischemic stroke. Molecular neurobiology 55 (2018): 7153-7163. DOI:10.1007/s12035-018-0910-6
Amelparib Preparation Products And Raw materials
Tag:Amelparib(1227156-72-0) Related Product Information